BF-BIOlabs Licenses OGT's Array Patents | GenomeWeb
NEW YORK (GenomeWeb News) – Oxford Gene Technology has licensed the rights to make and market certain oligonucleotide microarrays using the company’s Southern array patents to BF-BIOlabs, OGT said today.
 
Under the license, BF-BIOlabs will be able to sell arrays and array-based services for identifying genes, SNPs, and gene expression analysis.
 
OGT said the license will remain valid for the lifetime of the patents. Financial terms of the agreement were not released.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.